# Phase 2 recurrence trials recruiting: 162 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 162 trials in phase 2 for recurrence that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 recurrence trials: 162 rows for $8.10, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 5 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/recurrence

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 162
- Recruiting or not yet: 162
- Read on: November 19, 2026

## Trials

The 25 newest of 162, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 3, 2026 | NCT07913594 | Zilovertamab Vedotin and Lenalidomide (ZiVLen) Therapy for Relapsed/Refractory Peripheral T-Cell Lymphoma | Olivia Newton-John Cancer Research Institute | Phase 2 | Not yet recruiting | Peripheral T-Cell Lymphoma Refractory | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07913594) |
| October 28, 2026 | NCT07901803 | Aspirin and PAClitaxel in Head & Neck Squamous Cell Carcinoma | Washington University School of Medicine | Phase 2 | Not yet recruiting | Head and Neck (HNSCC), Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Head and Neck... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07901803) |
| October 20, 2026 | NCT07883135 | Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell Lymphomas | National Research Center for Hematology, Russia | Phase 2 | Recruiting | Aggressive B-cell Non-Hodgkin Lymphoma (aNHL), Relapsed or Refractory B-cell Lymphoma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07883135) |
| October 15, 2026 | NCT07874737 | Mitoxantrone Hydrochloride Liposome Combined With Cladribine And Sotorasib For Relapsed Refractory Acute Myeloid Leukemia | The Affiliated People's Hospital of Ningbo University | Phase 2 | Not yet recruiting | Relapsed and Refractory Acute Myeloid Leukemia (RR-AML) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874737) |
| October 13, 2026 | NCT07870746 | Phase 2a Study to Assess Safety and Efficacy of Two 177Lu-TLX250 Dosing Regimens in Advanced Relapsed or Recurrent ccRCC | Telix Pharmaceuticals (Innovations) Pty Limited | Phase 2 | Not yet recruiting | ccRCC, Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), Renal Cell Cancer Metastatic, Renal Cell... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07870746) |
| October 7, 2026 | NCT07862946 | Inotuzumab as Post-Trasplantation Therapy for Adult High-risk B-cell Precursor Acute Lymphoblastic Leukemia | PETHEMA Foundation | Phase 2 | Not yet recruiting | Acute Lymphobkastic Leukemia, Adult | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07862946) |
| September 25, 2026 | NCT07840456 | Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP Trial | University Hospital, Basel, Switzerland | Phase 2 | Not yet recruiting | Carcinoma, Squamous Cell of Head and Neck HNSCC | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07840456) |
| September 15, 2026 | NCT07819591 | Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | SCLC, Recurrent | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07819591) |
| September 8, 2026 | NCT07807293 | Radioguided Salvage Pelvic Node Dissection in Oligometastatic Prostate Cancer - SALVAGE | University of British Columbia | Phase 2 | Not yet recruiting | Prostate Cancer, Oligometastatic | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07807293) |
| September 1, 2026 | NCT07796373 | Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase... | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 | Not yet recruiting | Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07796373) |
| August 28, 2026 | NCT07791498 | Teclistamab In Waldenstrom's Macroglobulinemia | Massachusetts General Hospital | Phase 2 | Not yet recruiting | Waldenstrom's Macroglobulinemia | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07791498) |
| August 24, 2026 | NCT07783100 | Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid Leukemia | The First Affiliated Hospital of Xiamen University | Phase 2 | Recruiting | Relapsed or Refractory Acute Myeloid Leukemia | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07783100) |
| August 24, 2026 | NCT07781891 | RAPID: Phase 2 Platform Trial Of Promising Drugs For AYA Patients With R/R Ewing Sarcoma & DSRCT | M.D. Anderson Cancer Center | Phase 2 | Not yet recruiting | Ewing Sarcoma | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07781891) |
| August 18, 2026 | NCT07771361 | BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma | Luminary Therapeutics | Phase 2 | Not yet recruiting | Non-Hodgkin Lymphoma Refractory/ Relapsed, Multiple Myeloma Refractory, Multiple Myeloma in Relapse, Non-Hodgkin... | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07771361) |
| August 13, 2026 | NCT07763496 | Relacorilant and Nab-Paclitaxel in Recurrent or Metastatic Cervical Cancer | ARCAGY/ GINECO GROUP | Phase 2 | Not yet recruiting | Recurrent or Metastatic Cervical Cancer | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07763496) |
| August 13, 2026 | NCT07763210 | Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma | Vanderbilt-Ingram Cancer Center | Phase 2 | Recruiting | Non-hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell... | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07763210) |
| August 5, 2026 | NCT07748364 | Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Relapsed/Refractory Diffuse Large B-cell Lymphoma, Relapsed/Refractory Mantle Cell Lymphoma | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07748364) |
| July 31, 2026 | NCT07738757 | SKB264 Plus KL-A167 in MSI-H/dMMR Advanced Gynecological Malignancies | Peking Union Medical College Hospital | Phase 2 | Not yet recruiting | Recurrent or Metastatic MSI-H/dMMR Gynecological Malignancies | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07738757) |
| July 17, 2026 | NCT07711483 | GLORY: Glofit-GemOx With Liso-Cel For Lymphoma | Massachusetts General Hospital | Phase 2 | Recruiting | Lymphoma, B-cell Lymphomas, Relapsed/Refractory Large B-cell Lymphoma, Large B-cell Lymphoma | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07711483) |
| July 14, 2026 | NCT07702851 | A Study of Polatuzumab Vedotin and Glofitamab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Within 12 Months After... | Yonsei University | Phase 2 | Not yet recruiting | Diffuse Large B-cell Lymphoma | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07702851) |
| July 10, 2026 | NCT07695740 | Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma | Excyte Biopharma Ltd | Phase 2 | Not yet recruiting | Relapsed or Refractory Multiple Myeloma (RRMM) | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07695740) |
| July 8, 2026 | NCT07689058 | CAR-T in Relapsed/Refractory Multiple Myeloma | Sponsor not shown (see the record) | Phase 2 | Recruiting | Multiple Myeloma Refractory, Multiple Myeloma in Relapse | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07689058) |
| July 7, 2026 | NCT07686588 | Sacituzumab Tirumotecan Plus Immunotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Recurrent or Metastatic Head and Neck Carcinoma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07686588) |
| July 6, 2026 | NCT07682675 | Study to Evaluate the Efficacy of Zanzalintinib in the Treatment of Relapsed or Metastatic Adenoid Cystic Carcinomas of the Head and Neck | UNICANCER | Phase 2 | Not yet recruiting | Adenoid Cystic Carcinoma of the Salivary Gland, Recurrence, Metastatic Disease | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07682675) |
| June 29, 2026 | NCT07672782 | Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva | GOG Foundation | Phase 2 | Not yet recruiting | Vulvar Carcinoma, Recurrent or Metastatic Vulvar Cancer, Squamous Cell Carcinoma Vulva | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07672782) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Sun Yat-sen University | 4 |
| Memorial Sloan Kettering Cancer Center | 4 |
| Massachusetts General Hospital | 4 |
| Institute of Hematology & Blood Diseases Hospital, China | 3 |
| Ruijin Hospital | 3 |
| Washington University School of Medicine | 3 |
| The First Affiliated Hospital of Xiamen University | 3 |
| Fudan University | 3 |
| Fondazione Italiana Linfomi - ETS | 2 |
| Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 2 |
| Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2 |
| Northern Jiangsu People's Hospital | 2 |
| Peking Union Medical College Hospital | 2 |
| Tianjin Medical University Cancer Institute and Hospital | 2 |
| UNICANCER | 2 |
| First Affiliated Hospital of Zhejiang University | 2 |
| Yale University | 2 |
| University of Miami | 2 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2 |
| University Health Network, Toronto | 2 |
| Yonsei University | 2 |
| American University of Beirut Medical Center | 1 |
| [Qilu Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/qilu-pharmaceutical-co-ltd) | 1 |
| Aadi Bioscience, Inc. | 1 |
| Ryvu Therapeutics SA | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 58 |
| United States | 46 |
| France | 14 |
| Canada | 10 |
| Italy | 10 |
| Spain | 9 |
| Australia | 8 |
| South Korea | 6 |
| Germany | 6 |
| Japan | 4 |
| Poland | 3 |
| United Kingdom | 3 |
| Taiwan | 3 |
| Singapore | 2 |
| Denmark | 2 |
| Sweden | 2 |
| Brazil | 2 |
| Switzerland | 2 |
| Lebanon | 1 |
| Israel | 1 |
| Greece | 1 |
| Serbia | 1 |
| Austria | 1 |
| Czechia | 1 |
| Norway | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Ambulance services in the United States](https://specstream.ai/data/businesses/ambulance-services/united-states)
- [Dermatology practices in the United States](https://specstream.ai/data/businesses/dermatology-practices/united-states)
- [IT service companies in the United States](https://specstream.ai/data/businesses/it-service-companies/united-states)
- [Real estate law firms in the United States](https://specstream.ai/data/businesses/real-estate-law-firms/united-states)
- [Apparel manufacturers in the United States](https://specstream.ai/data/businesses/apparel-manufacturers/united-states)
- [Disability law firms in the United States](https://specstream.ai/data/businesses/disability-law-firms/united-states)
